Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2018 | Cardio-oncology: a new medical field

Alex Lyon • 6 Apr 2018
BSH 2018
General

With the increasing life expectancy of cancer patients, the long-term consequences of cancer therapy are becoming an increasing issue. Anthracycline-induced heart failure is a classic example of an adverse cardiovascular effect of cancer therapy. Here, Alex Lyon, MA, BM BCh, PhD, FRCP, from Imperial College, London, UK, discusses the recent development of cardio-oncology as a recognized sub-specialty dedicated to the prevention, identification and treatment of cardiovascular complications in patients receiving cancer therapy. This interview was recorded at the British Society for Hematology (BSH) 2018 Annual Scientific Meeting, Liverpool, UK.

More from Alex Lyon

1:27
European Society of Cardiology: 2022 cardio-oncology guidelines
Alex Lyon • 3 Apr 2022
2:37
Reducing the risk of cardiovascular toxicities when treating hematological malignancies
Alex Lyon • 3 Apr 2022
1:54
Future directions for cancer therapy-related cardiac dysfunction
Alex Lyon • 6 Apr 2018

Related Videos

2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
1:12
The contribution of viral infections, such as EBV, to post-transplant lymphoproliferative disease
Susan Prockop • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals